- Select a blog category
By Samrina Bhatti, Manager and Dr Karen Kirkham, Chief Medical Officer
It is with great pleasure, I introduce Karen Kirkham who joins us at Deloitte as a Partner in our Public Sector Health and Social Care practice and the firm’s new Chief Medical Officer(CMO). Karen has been a practising GP for over 30 years and, from 2016 to July 2021 was also the Clinical lead for the Dorset Integrated Care System, as well as a National Clinical Advisor for Systems Development and Population Health Management and Primary Care Transformation with NHSE/I. Karen will be continuing her clinical practice one-day-a-week.
By Karen Taylor, Director, and Pratik Avhad, Senior Analyst, Centre for Health Solutions
This week the Deloitte Academy hosted its latest ‘The Deloitte Quarterly Forward Look’ where I and my fellow Insight colleagues discussed what we are seeing and expect to happen over the next three months. My focus was on the public health impact of the COVID-19 pandemic, both globally and in the UK. I was supported in my preparation for this webinar by research from my senior analyst, Pratik Avhad, who has supported me in understanding the evolving story of the pandemic over the past 18 months. I thought I would use this week’s blog to share some of our latest research on infection numbers, vaccinations and the likelihood of another lockdown in the coming months.
By Pratik Avhad, Senior Analyst, and Maria João Cruz, PhD, Assistant Research Manager, Centre for Health Solutions
Since the start of the COVID-19 pandemic, more than 218 million cases and over 4.5 million COVID-related deaths have been reported worldwide, numbers that continue to grow.1 As long as the SARS-CoV-2 virus is in circulation, it will have an opportunity to mutate into potentially more infectious strains and remain an ever-moving target. Vaccines are an essential tool in the arsenal to combat this pandemic.2 To date, six vaccines have been approved for emergency or full use by at least one WHO-recognised stringent regulatory authority. All have been proven to be safe and effective at preventing severe disease, hospitalisation and COVID-related death.3 Vaccine developers are using a variety of technologies and techniques from the tried and tested to completely novel approaches. The first vaccine to receive emergency approval was a first-in-class synthetic messenger RNA (mRNA) vaccine4, making RNA a household word. Even though mRNA technology itself is not new, its clinical reality is still nascent and this blog explores its concept and considers what future uses might emerge.
By Krissie Ferris, Research Analyst, Centre for Health Solutions
This is my last week in the Deloitte Centre for Health Solutions, my home at Deloitte for almost two years. I'm not moving far though as I’m joining Deloitte’s Technology Digital Risk (TDR) Public Sector Health team, where I’ll be working with clients across the NHS and the wider healthcare industry to digitise ways of working and to help realise the huge opportunities for operational efficiencies and improved patient outcomes that can be enabled through technology. Having started my career in the NHS, I’m excited to start this new chapter and bring with me the knowledge and skills I’ve developed in my research role at the Centre. This blog reflects on my fabulous time at Deloitte so far and shares some of the reasons I’m looking forward to joining the health team.
By Emma Gould, Manager, and Scott Grainger, Manager, Deloitte Risk Advisory
When the first wave of COVID-19 hit the UK, the NHS had to prepare for worst-case scenarios. Plans for temporary hospitals and surge critical care capacity were rapidly drawn up, non-urgent services were significantly scaled down, and large numbers of staff were redeployed to ensure the NHS would be able to care for the impending rush of severely ill patients. More than a year on, and in the midst of another surge in positive cases, the true scale of the pandemic’s impact on wider health provision is starting to emerge as hospitals face an uphill battle to restore and recover elective services alongside increasing COVID-19 admissions.
By Jonathan Fox, Managing Director, Deloitte Consulting US, and Hanno Ronte, Partner, Monitor Deloitte UK
Let’s talk about trust, specifically, consumer trust in biopharmaceutical (biopharma) manufacturers. Why do consumers trust or distrust biopharma companies? What do consumers think biopharma should do to increase trust? Can companies use digital capabilities to build, or in some cases rebuild, consumer trust? Why is trust important? These were some of the questions we discussed at a digital leader’ roundtable event at LSX’s World Congress USA event which Deloitte was a sponsor. This week’s blog provides our personal take on the key takeaways to emerge from that discussion.
By Samrina Bhatti, Manager, Centre for Health Solutions
The World Health Organisation estimates that, between 2030 and 2050, climate change will be responsible for approximately 250,000 additional deaths per year.1 Climate change affects a number of social and environmental determinants of health – clean air, safe drinking water, availability of sufficient food and secure shelter - and experts consider it as the next public health crisis.2 ‘Net Zero’ has been adopted by the UK, the EU, and many other countries around the world as the best strategy to protect global populations from rising temperatures. This week is ‘NetZero Week,’ the UK’s national awareness week aimed at highlighting climate change challenge and providing expert advice and information to help individuals and businesses understand the challenge and how to benefit from making changes.3 This week’s blog builds on NetZero campaign to explores climate change’s impact on public health and how healthcare organisations can prioritise net zero efforts.
By Dominique Walcot, Consultant and Dan Donaghy, Director, Deloitte Consulting
Over the past few years, health regulators have been increasingly looking to use emerging technologies and new business models to reduce the burden of compliance and drive better efficiencies and regulatory outcomes. Recent changes to health legislation had been driving reform, and these changes were rapidly accelerated by the COVID-19 pandemic. Overnight, health regulators were unable to complete traditional face-to-face inspections or registration checks and had to rapidly evolve their models; deploying remote technologies and new ways of working to ensure key activities could be completed to keep patients and staff as safe as possible. For some regulators, this even meant moving into new areas of operations – such as vaccination monitoring. This blog discusses changes to the UK health regulatory system, growing trends in safety and quality regulation, and lessons learnt from the COVID-19 pandemic.
By Lisa Dittmar, Manager, Deloitte Consulting
Healthcare organisations face an exciting but uncertain future. In the face of the COVID-19 recovery, future health crises, the climate crisis, shifting models of care and increased digitalisation, generations of leaders will need to battle increasing levels of complexity alongside continuing uncertainty and make decisions quickly with incomplete information. Ultimately, however, they have less than 30 years to develop a net zero healthcare system that operates within a net zero economy. While this is daunting it’s also exciting and, if achieved, the future will be bright.
By Dr Maria João Cruz, PhD, Assistant Manager, Centre for Health Solutions
Following the launch of our eleventh annual report ‘Seeds of change: Measuring the return from pharmaceutical innovation 2020’, our UK and US Life Sciences R&D lead partners, Colin Terry and Neil Lesser, hosted a webinar with R&D executives from Pfizer and Novartis to discuss R&D productivity. The discussion also covered the impact of the COVID-19 pandemic on productivity. This week’s blog covers the main takeaways from this insightful discussion that resonated the most with me.
Integrating climate commitments into Pharma’s DNA: Good for business, the environment and public health
By Emily May, Research Analyst, Centre for Health Solutions
Last week, our Life Sciences & Healthcare UK leader James Gregson moderated a Reuters’ webinar, Pharma’s climate goals: The roadmap to delivery, with leaders from AstraZeneca, Roche and Health Care Without Harm. The discussion focused on the current pharma sustainability landscape and how to collaborate, accelerate and deliver climate commitments and embed them into pharma organisations’ DNA.1 Healthcare’s carbon footprint is estimated to have increased by 40 per cent since 1990 providing the pharma industry with an opportunity and responsibility to make a real difference. While there are promising signs across the sector of an increased willingness and commitment to counteract climate change, including adopting a more stringent timetable by which to meet carbon net-zero goals, the panel discussion and the focus of this blog is whether the pace of change is advancing fast enough and what more do companies need to do?